Displaying 13 - 24 of 37
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Displaying 13 - 24 of 37